Lymphoproliferative disorders Clinical Trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules of (tal+tec+dara) the treatment combinations …

human chorionic gonadotropin
lenalidomide
bortezomib
refractory multiple myeloma
carfilzomib
  • 0 views
  • 17 Sep, 2021
  • 14 locations
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

measurable disease
human chorionic gonadotropin
lenalidomide
bortezomib
refractory multiple myeloma
  • 0 views
  • 17 Sep, 2021
  • 28 locations
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become nonresponsive to treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose …

measurable disease
bortezomib
cancer
refractory multiple myeloma
dexamethasone
  • 0 views
  • 22 Sep, 2021
  • 33 locations
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies

This trial is an open-label, safety trial of GEN3014 (HexaBody-CD38). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH), and an expansion part phase 2a.

  • 0 views
  • 11 Sep, 2021
  • 9 locations
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S zary Syndrome (SS)

The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Szary Syndrome that have recently achieved disease control with previous systemic therapy.

chemotherapy regimen
resminostat
sezary syndrome
bexarotene
maintenance treatment
  • 898 views
  • 17 Sep, 2021
  • 92 locations
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma OPTIMUM Trial

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by …

chemotherapy regimen
progressive disease
bone marrow procedure
neutrophil count
lenalidomide
  • 0 views
  • 23 Sep, 2021
  • 136 locations
A Study of Bortezomib Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial …

chemotherapy regimen
neutrophil count
erythropoietin
measurable disease
human chorionic gonadotropin
  • 3 views
  • 23 Sep, 2021
  • 121 locations
A Phase 1/2 Open-label Multicenter Dose Escalation and Dose Expansion Study of the Safety Tolerability and PK of HPN217 in Patients With R/R MM

An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

measurable disease
renal function
refractory multiple myeloma
neutrophil count
platelet count
  • 6 views
  • 16 Sep, 2021
  • 13 locations
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, …

electrophoresis
hypertension
bortezomib
platelet count
revlimid
  • 0 views
  • 22 Sep, 2021
  • 374 locations
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Multiple Myeloma)

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML). VOB560 and MIK665 are selective and …

b-cell lymphoma
tumor cells
leukemia
refractory multiple myeloma
multiple myeloma
  • 0 views
  • 17 Sep, 2021
  • 4 locations